hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06354283 id: Progresif briefTitle: Progressive Muscle Relaxation Exercises Women With Low Sexual Satisfaction Sexual Satisfaction and Functioning of Women and Their Partners overallStatus: COMPLETED date: 2023-04-10 date: 2024-01-30 date: 2024-02-08 date: 2024-04-09 date: 2024-04-09 name: Halic University class: OTHER briefSummary: This study was conducted to investigate the effect of progressive muscle relaxation exercises on sexual satisfaction and functioning of women and their partners in women with low sexual satisfaction.
Method: The single-blind, randomized controlled study was conducted between April 2023 and January 2024. The sample of the study was women with low sexual satisfaction and their partners were randomized into two groups as intervention and control. Each group consisted of 120 couples, n=60. The women in the intervention group were given progressive muscle relaxation techniques three times a week for four weeks. The results of the study focused on the effect on sexual satisfaction and functioning of men and women. conditions: Women With Low Sexual Satisfaction conditions: Partners of Women With Low Sexual Satisfaction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Intervention Group and Control Group primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The progressive relaxation intervention and follow-up was conducted by the researcher who was not blinded to the interventions (PSI). Randomization was performed by another academic who was not an investigator in the study. In order to avoid bias, the researcher who conducted the intervention did not participate in any step of the pre-test, post-test and statistical evaluation process. Group information was not shared with the statistician who performed the analysis. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ACTUAL name: Progressive Muscle Relaxation Exercises measure: Sexual Satisfaction measure: Sexual Function sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Fatma Şule Bilgiç city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06354270 id: 300104 briefTitle: A Clinical Study to Evaluate the Anti-Sensitivity Efficacy of a Stannous Fluoride Toothpaste in a Population of Dentin Hypersensitivity Sufferers overallStatus: ACTIVE_NOT_RECRUITING date: 2024-04-11 date: 2024-06-24 date: 2024-06-24 date: 2024-04-09 date: 2024-04-25 name: HALEON class: INDUSTRY briefSummary: The aim of this study is to confirm the clinical Dentin Hypersensitivity (DH) efficacy of a 0.454 percent (%) Stannous Fluoride (SnF2) toothpaste. conditions: Dentin Sensitivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 115 type: ACTUAL name: Stannous fluoride toothpaste name: Regular fluoride toothpaste (Crest Cavity Protection) measure: Change from Baseline in Schiff Sensitivity Score at Day 56 measure: Change from Baseline in Tactile Threshold at Day 56 measure: Change from Baseline in Schiff Sensitivity Score at Day 28 measure: Change from Baseline in Tactile Threshold at Day 28 measure: Change from Baseline in Impact on Everyday Life (Section 1 of Dentin Hypersensitivity Experience Questionnaire [DHEQ-48], Question [Q]7-9) at Days 28 and 56 measure: Change from Baseline in DHEQ Total Score (Section 2, Q1-34) at Days 28 and 56 measure: Change from Baseline in DHEQ Restrictions Domain (Section 2, Q1-4) Score at Days 28 and 56 measure: Change from Baseline in DHEQ Adaptation Domain Score (Section 2, Q5-16) at Days 28 and 56 measure: Change from Baseline in DHEQ Social Impact Domain (Section 2, Q17-21) Score at Days 28 and 56 measure: Change from Baseline in DHEQ Emotional Impact Domain (Section 2, Q22-29) Score at Days 28 and 56 measure: Change from Baseline in DHEQ Identity Domain (Section 2, Q30-34) Score at Days 28 and 56 measure: Change from Baseline in Global Oral Health (Section 2, Q35) Score at Days 28 and 56 measure: Change from Baseline in Effect on Life Overall (Section 2, Q36-39) Score at Days 28 and 56 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Family and Cosmetic Dentistry, All Sums Research Center Ltd. city: Melbourne state: Florida zip: 32940 country: United States lat: 28.08363 lon: -80.60811 hasResults: False
nctId: NCT06354244 id: 2023-183-KY-02 briefTitle: Electroacupuncture of Different Treatment Frequency in Chronic Urinary Retention Caused by Lower Motor Neuron Lesions overallStatus: RECRUITING date: 2024-04 date: 2024-09 date: 2024-09 date: 2024-04-09 date: 2024-04-09 name: Guang'anmen Hospital of China Academy of Chinese Medical Sciences class: OTHER briefSummary: The aim of this study is to compare the effects of electroacupuncture of different frequency in patients with chronic urinary retention caused by lower motor neuron lesions conditions: Urinary Retention conditions: Lower Motor Neurone Lesion studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Electroacupuncture of 2 sessions per week name: Electroacupuncture of 3 sessions per week name: Electroacupuncture of 4 sessions per week measure: The response rate. measure: The response rate. measure: The change in post void residuals (PVR) from baseline. measure: The change in the proportion of patients reporting severe urinating difficulty from baseline. measure: The change in the proportion of patients having stool retention from baseline. measure: The change in the proportion of patients requiring catheterization from baseline. measure: The proportion of patients reporting much better or moderately better regarding the Patient Global Impression of Improvement (PGI-I). measure: The proportion of patients having recurrent symptomatic UTI, hydroureter, or hydronephrosis. sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Guang'anmen Hospital, China Academy of Chinese Medical Sciences status: RECRUITING city: Beijing country: China name: Zhishun Liu, PhD role: CONTACT phone: +861088002331 email: zhishunjournal@163.com name: Min Yang role: CONTACT phone: +8618810268077 email: yangmin2019@yeah.net lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06354231 id: RC48-C012 briefTitle: DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC overallStatus: RECRUITING date: 2023-07-20 date: 2026-12-30 date: 2026-12-30 date: 2024-04-09 date: 2024-04-11 name: Fudan University class: OTHER briefSummary: Approximately 20 participants will be enrolled in the study to evaluate the efficacy and safety of the combination of DV (DV, 2.0 mg/kg, intravenously administered every 2 weeks) and toripalimab (toripalimab, 3.0mg/kg, intravenously administered every 2 weeks). Subjects will receive 6 cycles of DV and toripalimab, followed by laser surgery to remove ureteral or renal pelvis tumors, followed by 12 cycles of DV and 1 year of toripalimab consolidation therapy. Efficacy and safety were evaluated by cystoscopy, ureteroscopy, laboratory tests, and imaging examinations after treatment. conditions: Renal Insufficiency conditions: Upper Urinary Tract Urothelial Carcinoma conditions: Solitary Kidney studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: DV name: Toripalimab name: Laser surgery measure: Kidney-intact disease-free survival, KI-DFS measure: Time to progression, TTP measure: Time to RNU measure: Disease-specific survival time, DSS measure: Overall survival measure: 3m complete remission sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center status: RECRUITING city: Shanghai country: China name: dingwei ye role: CONTACT phone: 64175590-82800 lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06354218 id: GXL-005 briefTitle: Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age overallStatus: RECRUITING date: 2023-12-01 date: 2025-12-01 date: 2027-12-01 date: 2024-04-09 date: 2024-04-09 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: This study is a Single Arm, Prospective, Exploratory, Single Center Phase II Clinical Study to evaluate the effectiveness of the combination of Serplulimab and Concurrent Chemoradiotherapy in the treatment of elderly patients with locally advanced esophageal cancer who cannot be treated surgically.Subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria. conditions: Esophageal Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Serplulimab measure: mPFS measure: ORR measure: OS measure: DOR measure: Toxic side reactions sex: ALL minimumAge: 75 Years stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: Jiangsu zip: 210009 country: China name: Xiaolin MM Ge, PHD role: CONTACT phone: 13951818797 email: doctorsxl@163.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06354205 id: 24-3.1T/98 briefTitle: Comparison of Salivary Procalcitonin (PCT) Levels and Serum PCT Levels overallStatus: RECRUITING date: 2024-06-01 date: 2025-03-01 date: 2025-04-01 date: 2024-04-09 date: 2024-04-09 name: Ege University class: OTHER name: THE SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TÜRKİYE briefSummary: Recently, it has been seen that investigations from saliva samples could be an alternative to those from blood samples. Saliva collection is a simple, non-invasive, cost-effective, and relatively easy method, making it potentially suitable as a new diagnostic tool in pediatric patients. In the current literature, elevated levels of saliva CRP, TNF-α, IL-6, and IFN-γ have been reported in inflammatory conditions. However, while there are animal studies suggesting the use of saliva PCT levels for focal diseases such as gingival inflammation and periodontitis and as a potential tool for non-invasive detection of sepsis, there is no human study regarding its use in systemic infections.
The aim of this study is to evaluate the correlation between serum PCT levels and saliva PCT levels in children suspected of SBE and to determine the diagnostic value of saliva PCT. conditions: Bacterial Infections conditions: Children, Only conditions: Procalcitonin conditions: Saliva studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 160 type: ESTIMATED name: Sliva Procalcitonin measure: Correlation measure: Diagnose sex: ALL minimumAge: 0 Years maximumAge: 1 Year stdAges: CHILD facility: Ege University School of Medicine status: RECRUITING city: İzmir zip: 35100 country: Turkey name: Caner Turan role: CONTACT lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06354192 id: 0450 briefTitle: Precision Nudging for Hypertension Management: Observational Study overallStatus: NOT_YET_RECRUITING date: 2024-04-11 date: 2025-10-11 date: 2026-10-11 date: 2024-04-09 date: 2024-04-09 name: Lirio class: INDUSTRY name: Cone Health briefSummary: The purpose of the proposed observational study is to explore the relations between data-driven personalization and equitable health outcomes in a digital health intervention (DHI) for hypertension management. In the current intervention, behavioral reinforcement learning is applied to personalize intervention content to maximize the behavioral outcomes of three target behaviors critical for effective hypertension management: clinical encounters, medication adherence, and self-monitoring of blood pressure (SMBP). conditions: Hypertension studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 12000 type: ESTIMATED name: Precision Nudging for Hypertension Management measure: Clinical encounter behavioral outcome measure: Blood pressure reading clinical outcome measure: Engagement measure: Medication adherence behavioral outcome measure: Self-monitoring of blood pressure behavioral outcome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06354179 id: 87RI23_0031 (EASY) briefTitle: Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY) acronym: EASY overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-07-01 date: 2027-07-01 date: 2024-04-09 date: 2024-04-11 name: University Hospital, Limoges class: OTHER briefSummary: World Health Organization considers non-adherence has a strong negative impact on the health of patients with chronic diseases. In transplantation, adherence to immunosuppressive drug regimens associates with late rejection and graft loss making it a critical determinant of patient outcome. The prevalence of non-adherence in transplant patients, including liver transplant patients, can be as high as 40%. Among others, life-long intake and complexity of immunosuppressive regimen make patients prone to non-adherence. For instance, non-adherence is more prevalent among patients with higher numbers of immunosuppressive drugs. One of the most commonly cited causes of non-adherence is forgetfulness and disruptions in routine, with the evening dose of twice daily regimens being the most likely to be affected6. Besides non-adherence, the constraints generated in everyday life by immunosuppression (including timely and regular drug intake) and the complexity of the immunosuppressive regimens represent a burden for the patients and are probably associated with a health-related quality of life deterioration. Therefore, long-term adherence and quality of life after liver transplantation might be improved by using a well-tolerated and easy-to-handle immunosuppressive regimen.
The immunosuppressive regimen after liver transplantation is in most cases based on different combinations of tacrolimus, mycophenolate mofetil and corticosteroids. While corticosteroids are administered once daily, tacrolimus can be administered either twice-daily (BID) as an immediate-release, or once-daily (QD) as an extended-release formulation. Among once-daily tacrolimus formulations, LCP-tacrolimus (ENVARSUS XR®) is approved for the prevention of transplant rejection in adult liver allograft recipients. It has demonstrated similar outcomes compared to immediate-release tacrolimus BID, in both kidney and liver transplantation. Mycophenolate has only been approved for BID administration, preventing from taking all immunosuppressive drugs once daily. Yet, single daily dosing would probably contribute to better adherence and quality of life in patients receiving a life-long treatment.
The narrow therapeutic index and wide pharmacokinetic variability of tacrolimus and mycophenolate justify individual dose adjustment by means of therapeutic drug monitoring (TDM), in order to minimize the risk of acute rejection and the occurrence of adverse events. For tacrolimus, TDM is generally based on the trough concentration (C0) and sometimes on the area under the concentration-time curve (AUC), while for mycophenolate it should be based on the AUC of MPA. However, the dose adjustment of MMF in liver transplant patients is most of the time performed a posteriori, based on clinical signs of inefficacy of toxicity.
Limited sampling strategies with maximum a posteriori Bayesian estimation have been developed by our team for both molecules in adult liver transplant patients to estimate their AUC, which is considered the best marker of exposure for both. Therefore, tacrolimus AUC0-24h can be estimated by Bayesian estimation using samples collected before administration (C0), 8 (C8h) and 12 (C12h) hours after the administration of ENVARSUS XR®, or 1 and 3 hours after the administration of PROGRAF® and ADVAGRAF®. For mycophenolate, the MPA AUC can be estimated using samples collected 20 min, 1 and 3 hours after MMF administration, by Bayesian estimation.
Even if limited to 2 or 3 blood samples, tacrolimus TDM for ENVARSUS® requires late sampling (12h post-dose). To overcome the necessity of a longer hospital stay, microsampling devices (MSD) such as the Volumetric absorptive microsampling (VAMS®) device (Mitra®) can be used by the patients to take samples themselves, at home. Moreover, they are less invasive than venipuncture and collect low but accurate volumes of blood for analysis.
nctId: NCT06354166 id: 2023-A02745-40 briefTitle: Study Human Digital Support Transitional Care acronym: SUNH-ST overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-03 date: 2025-03 date: 2024-04-09 date: 2024-04-09 name: Divoluci class: OTHER briefSummary: The purpose of the study is to compare the effectiveness of Divomed in organising complex hospital discharges with a conventional organisation. Effectiveness will be assessed by reducing the length of stay of patients in geriatric short-stay care. conditions: Aging studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Interventional, randomised (1:1 ratio), single-centre study primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: open-label study count: 150 type: ESTIMATED name: Unscheduled hospital admissions measure: length of stay sex: ALL minimumAge: 75 Years stdAges: OLDER_ADULT facility: CHRU de Tours - Hôpital Bretonneau city: Tours zip: 37044 country: France name: Wassim GANA, MD role: CONTACT email: w.gana@chu-tours.fr lat: 47.38333 lon: 0.68333 hasResults: False
nctId: NCT06354153 id: 0305898 briefTitle: Polarity Management Training Program for First Line Nurse Manager overallStatus: COMPLETED date: 2022-12-01 date: 2023-04-30 date: 2023-04-30 date: 2024-04-09 date: 2024-04-09 name: Matrouh University class: OTHER briefSummary: Polarities are vital issues in healthcare systems. Nursing is a profession riddled with polarities. If first-line nurse managers are well trained to manage polarities in the workplace, this could lead to positive outcomes for nurses, nurse managers and organization performance. conditions: Intervention conditions: Knowledge, Attitudes, Practice studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: A quasi-experimental design utilized one group for pre-, post, and follow-up intervention. whoMasked: PARTICIPANT count: 60 type: ACTUAL name: Polarity Management Training Program measure: Questionnaire to measure nurse managers' knowledge measure: Nursing polarity case study situations to assess first-line nurse manager's ability to differentiate between problems to solve and polarities to manage measure: Questionnaire to measure creativity behavior of first-line nurse managers measure: questionnaire to measure intrinsic work motivation among first-line nurse managers sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Nursing, Matrouh University city: Marsa Matruh zip: 002 country: Egypt lat: 31.3529 lon: 27.23725 hasResults: False
nctId: NCT06354140 id: WeGuo briefTitle: PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY overallStatus: RECRUITING date: 2024-04-07 date: 2027-04-30 date: 2028-04-30 date: 2024-04-09 date: 2024-04-09 name: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University class: OTHER briefSummary: To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant immunotherapy combined with chemotherapy conditions: Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE maskingDescription: The study was a one-arm open study count: 45 type: ESTIMATED name: Tegafur measure: 1-year DFS rate measure: Overall survival measure: Progression-free survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Army Medical Center of the People's Liberation Army status: RECRUITING city: Chongqing state: Chongqing zip: 400042 country: China name: Guo role: CONTACT phone: +8613527323568 email: gyguowei@hotmail.com lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06354127 id: DW_DWP450009 briefTitle: DWP450 for Treating Moderate to Severe Glabellar Lines overallStatus: COMPLETED date: 2020-08-12 date: 2020-11-24 date: 2021-01-25 date: 2024-04-09 date: 2024-04-09 name: Daewoong Pharmaceutical Co. LTD. class: INDUSTRY briefSummary: A multi-center, randomized, double-blind, positive drug-controlled clinical study to evaluate the safety and efficacy of Botulinum Toxin Type A for Injection in the treatment of moderate to severe glabellar lines conditions: Moderate to Severe Glabellar Lines studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 473 type: ACTUAL name: DWP450 name: Botox® measure: Response rate based on the investigator's on-site assessment of severity of glabellar lines at maximum frown sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine city: Shanghai state: Shanghai country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06354114 id: SYHX2011-003 briefTitle: A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10-31 date: 2026-12 date: 2024-04-09 date: 2024-04-09 name: CSPC Ouyi Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011 conditions: Advanced Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: SYHX2011 measure: Objective Response Rate (ORR) by Investigator measure: Progression-Free-Survival (PFS) measure: Time to progression (TTP) measure: Incidence of adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Harbin Medical University Cancer Hospital city: Harbin state: Heilongjiang country: China name: Qingyuan Zhang role: CONTACT phone: 86-13313612989 email: 13313612989@163.com lat: 45.75 lon: 126.65 hasResults: False